Aaron Gu Email & Phone Number

Mr. Gu focuses on corporate, regulatory compliance, and transactional services for life sciences, biopharmaceutical, medical and healthcare industries, including biosecurity and human genetic resource issues, clinical trial matters, product marketing authorizations, GxP compliance, drug licensing and collaboration (license in/out), as well as regulatory issues involved in venture capital and private equity investments, mergers and acquisitions, and foreign and outbound investments in the life sciences industries. Mr. Gu also provides advocacy advice on draft laws and regulations released by the NMPA and other Chinese governmental authorities. Specifically, Mr. Gu's services cover a full range of products including drugs (biologics and chemical drugs), medical devices, IVDs, cosmetics, general foods, special foods (health foods, foods for special medical purposes, and infant formulas), animal drugs, animal foods, etc. Mr. Gu has co-authored the China chapter of Editions 7, 8, 9, and 10 (2019-2022) of "The Life Sciences Law Review", the China chapter of Editions 6, 7 (2022-2023) of "The Healthcare Law Review", Chambers Life Sciences Global Practice Guide (2022-2023) and Chambers Healthcare: Medical Devices Global Practice Guide (2023), and has been interviewed by Mr. Gu has been interviewed by Blue View, Caixin, China Business Network, Dutch Financial Daily, Faxian Magazine, Healthcare Executive, International Pharmaceutical News for China, Jiemian, Thomson Reuters and other media.

Listed skills include Corporate Law, Legal Research, International Law, Joint Ventures, and 6 others.